ZIMV vs. NGNE, LXRX, KRRO, ALVO, HRTX, FATE, LXEO, BMEA, ANNX, and ITOS
Should you be buying ZimVie stock or one of its competitors? The main competitors of ZimVie include Neurogene (NGNE), Lexicon Pharmaceuticals (LXRX), Korro Bio (KRRO), Alvotech (ALVO), Heron Therapeutics (HRTX), Fate Therapeutics (FATE), Lexeo Therapeutics (LXEO), Biomea Fusion (BMEA), Annexon (ANNX), and iTeos Therapeutics (ITOS). These companies are all part of the "medical" sector.
ZimVie (NASDAQ:ZIMV) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.
In the previous week, Neurogene had 6 more articles in the media than ZimVie. MarketBeat recorded 14 mentions for Neurogene and 8 mentions for ZimVie. ZimVie's average media sentiment score of 0.86 beat Neurogene's score of 0.21 indicating that ZimVie is being referred to more favorably in the media.
Neurogene has a net margin of 0.00% compared to ZimVie's net margin of -56.31%. ZimVie's return on equity of 2.01% beat Neurogene's return on equity.
95.6% of ZimVie shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 3.0% of ZimVie shares are held by insiders. Comparatively, 1.6% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
ZimVie currently has a consensus price target of $17.33, indicating a potential upside of 1.84%. Neurogene has a consensus price target of $47.25, indicating a potential upside of 41.85%. Given Neurogene's stronger consensus rating and higher probable upside, analysts plainly believe Neurogene is more favorable than ZimVie.
Neurogene has lower revenue, but higher earnings than ZimVie.
Neurogene received 10 more outperform votes than ZimVie when rated by MarketBeat users. Likewise, 100.00% of users gave Neurogene an outperform vote while only 7.14% of users gave ZimVie an outperform vote.
ZimVie has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.
Summary
Neurogene beats ZimVie on 8 of the 15 factors compared between the two stocks.
Get ZimVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIMV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZIMV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
